Menu
GeneBe

SMN1

survival of motor neuron 1, telomeric, the group of SMN complex|Tudor domain containing

Basic information

Region (hg38): 5:70925029-70953942

Previous symbols: [ "SMA@", "SMA" ]

Links

ENSG00000172062NCBI:6606OMIM:600354HGNC:11117Uniprot:Q16637AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • spinal muscular atrophy (Definitive), mode of inheritance: AR
  • spinal muscular atrophy, type 1 (Strong), mode of inheritance: AR
  • spinal muscular atrophy, type II (Strong), mode of inheritance: AR
  • spinal muscular atrophy, type III (Strong), mode of inheritance: AR
  • spinal muscular atrophy, type IV (Strong), mode of inheritance: AR
  • spinal muscular atrophy, type 1 (Definitive), mode of inheritance: AR
  • spinal muscular atrophy, type 1 (Supportive), mode of inheritance: AR
  • spinal muscular atrophy, type II (Supportive), mode of inheritance: AR
  • spinal muscular atrophy, type III (Supportive), mode of inheritance: AR
  • spinal muscular atrophy, type IV (Supportive), mode of inheritance: AR
  • spinal muscular atrophy, type IV (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Spinal muscular atrophy, type I; Spinal muscular atrophy, type II; Spinal muscular atrophy, type III; Spinal muscular atrophy, type IVARGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingMusculoskeletal; Neurologic7658877; 8551862; 7813012; 8968751; 8900234; 8782046; 8882869; 9245983; 10735271; 9056553; 10339583; 14705979; 17998484; 16775228; 18337729; 18941424; 19050931; 19716110; 1978076; 20301526
Valproate has been reported as being beneficial

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the SMN1 gene.

  • not provided (59 variants)
  • not specified (36 variants)
  • Spinal muscular atrophy (27 variants)
  • Werdnig-Hoffmann disease (14 variants)
  • Kugelberg-Welander disease (9 variants)
  • Spinal muscular atrophy, type II (7 variants)
  • Spinal muscular atrophy, type IV (2 variants)
  • Werdnig-Hoffmann disease;Spinal muscular atrophy, type IV;Spinal muscular atrophy, type II;Kugelberg-Welander disease (1 variants)
  • Spinal muscular atrophy, type II;Kugelberg-Welander disease;Werdnig-Hoffmann disease;Spinal muscular atrophy, type IV (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the SMN1 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
2
clinvar
3
clinvar
5
missense
5
clinvar
8
clinvar
19
clinvar
32
nonsense
6
clinvar
3
clinvar
9
start loss
0
frameshift
8
clinvar
6
clinvar
2
clinvar
16
inframe indel
0
splice donor/acceptor (+/-2bp)
2
clinvar
2
clinvar
4
splice region
6
1
7
non coding
4
clinvar
17
clinvar
1
clinvar
6
clinvar
28
Total 21 23 40 4 6

Variants in SMN1

This is a list of pathogenic ClinVar variants found in the SMN1 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
5-70925081-C-G Likely benign (Jul 06, 2018)1217482
5-70925090-C-T Benign (Jul 09, 2018)1236938
5-70925108-C-G Spinal muscular atrophy, type II • Kugelberg-Welander disease Pathogenic (Sep 21, 2022)9168
5-70925108-C-T Likely pathogenic (Feb 26, 2016)634935
5-70925124-C-CA Pathogenic (May 19, 2023)2690494
5-70925146-C-T Pathogenic (Aug 11, 2023)2684388
5-70925150-A-AGGATTCCG Spinal muscular atrophy, type II Pathogenic (Jan 19, 2016)634931
5-70925180-G-A Likely pathogenic (Feb 26, 2016)634933
5-70925229-C-T Benign (Jul 09, 2018)1279988
5-70936273-GAGTAGCTGGGATTACAGTCATGCACCACCACGCCCGGCTAATTTTGTATTTTTAGTAGAGAAGGGGTTTCTCCATGTTGAGGCTGGTCTCGAACTCCTGACCTCAGGTGATCTGCCCACCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACTGCGCCTGGCCCATTCTTTCTAATTCTATAAATTTGACTACTTAGTTACCTTACATAAATAAATTCTTATAGTTAGTGTTATTTTTGCTTCCATGCCTTTTTTGTTGTTGTTCATGCTCTTACTTGGAATGCGTTCTATTTTGTCTACCTATGCACATCCTGTTGGGTTTTTTTTTTTTTTGGGGGTTTTTTTTGTTTTTTTTTGTTTTTTTTTCCCAGACAAGGTCTCAATTTGTTACCCAGGCTGGAGTGCAGCGGCGCCATCTCCACTCACTGCATCCTCAACTTCCTGGGCCCAGGTGATCCTCTCGCCTCAGCCCCTGCAGGTAGCTGGGACTATAGGCATGTGCCACCATGCCCAGCTAAATTTGGTTTTTTTGTTTGTTTGTTTTTGAGACAGAGTCTCACTCTGTCACCCAGGCTGGAGTGCAGTGGCACAATCTCAGCTCACTGCAATCTCTGCCGCCCGGGTTCAAGTGATTCTCCTGCCTCAGCCTCCCAAGCAGCTGGGATTACAGGTGACTGCCACCACGCCAGCTAAGTTTTGTAGTTTTAGTAGAGATGGGGTTTCACCTTGTTGGCCATGCTGGTCTCGAACTCCTGACCTCGTGATCTGCCTGCTTCTGCCTCCCAAAGTGCTGGAATTACAGGCATGAGCCACCACGCCCGGCCAGAATTTTTGTATTTTTAGTAGACACAAGGTTCTTACCCTGTTGCCTAGGCTGGTCTGGAAGTCCTGGACTCAAGCAATTCACCTGCCTTGGCCTCCCAAAATGCTGGGATTACAAGCCACCATGCCCGGCCTAAATCCTGTTGTTTTGTTTTGTTTTATTTTGTTTTGTTTTGTTTTGTTTGTTTTTTGAGACAGAGTCTCGCTATGTCTCTCAGGCTGTAGTGCAGTGGCGCGATCTTGGCTCACTGCCACCTCTGCCTCCCAGGTTCAAGTGATTCTCCTGCCTCAGCCTCCCAAGTAGCTGGGATTACAGGCATGTGCTACTATGTCCGGCTAATTTTTGTATTTTTAGTAGAGACAGGGTTTCACCATGTTGGCCAGGCTGGTCTCGAACTCCTGACCTCGTGATCCACCCACCTCGGCCACCCAAAGTGCTGGGATTACAGGCGTGAGTGGTTTTTATTTCTTAGGCCGGTTTCCTCCATATGATCTTGCAGTAGACATTAATTTCTTTCCTTTTTAATTAAAATACTGTTTGTATTTCACATTTTGATGTTTGTTAAGATTTGTTTTATATTGTTTTTTGTTTTGTCTTGTGTGATAGTCTTAAATCCCTAGTTAGATAATAACTGGAGAGTACCATGTTTCTATATATCTCTCAGTGACTTGCACAGTGCTAGCAGATAGTGCTAAAAAATTATTTATTATTATTATTATTTTGTTATTGTTGTTGTTGTTGTTAGACAGGGTCTTCCTCTGTCACCCAGGCTAGAGGGCAATGGGATGATCATAGCTTACTGCAGCCTCCAACAACTGGGCTCATGTAATTCTCCTGCCTCAGCTTCCCAAGTAGCTGGGATTACAGGCATGAGCCACCATGTCTGGACAAAAATATTTCCAGGTGCAGTGGCTCATGCCTGTAATTCCCACACTTGGGAGGCCGAGCGAGGCTGGAGGATCACTTGAGCCTAGGAGTTCAAGACCAGCTTGGCTAAGATGGCGAGACCCCGTCCCTACAAAAAATTTTAAAAACTAGCCAGGCATGGTGGCATGCACCTATATTCCCAACTACTCAGTGGGCTGAGGTGGGAGGGTCATTTGAACACAGGAATTTGAGGGGAGAAAAAAAGAAGAGAGAAAGAGAAGTGAAGGAAGGAAGAAAGGAAGGAGGGAGGGAGAGAAGAAAGAAACGAAAGAAAGGAAAAGAAAAGGAAGGAAAGAAAATTGGTACCAGGAAAGCAGGAAAGGGAAATGGAAGTAAAAAAATAATAATAATAATAAAATGAAAATTGGTTAGTCACTATTAACAATTTGTATCCTTATAATCTGGAAACATTATAATTTCAAAAGAAAAAATATTCTTTGGATCATAGGTTCTGAGGTCAGAACAGCATTCCCGTAGTCTAGATGAAGTCAAGTTTTATCTGATCTTAATTGAAATAAATATAGCTGGCCTTGAACAAATCTACTCATGGTATGTGGATAGGAATTAAATTGTAGGGGCATTCACTTGATGGCATTCATTCTTAGAACATTTACCTATGTCTAGCTTTTGGAGTAAAGTCACATAACCTCTAACCAGGTAAGTTTCCTGTGGCTTTATTTAGGATTTTAAATACTCATTTTCAGTGTAATTTTGTTATGTGTGGATTAAGATGACTCTTGGTACTAACATACATTTTCTGATTAAACCTATCTGAACATGAGTTGTTTTTATTTCTTACCCTTTCCAGAGCGATGATTCTGACATTTGGGATGATACAGCACTGATAAAAGCATATGATAAAGCTGTGGCTTCATTTAAGGTATGAAATGCTTGCTTAGTCGTTTTCTTATTTTCTCGTTATTCATTTGGAAAGGAATTGATAACATACGATAAAGTGTTAAAGTACATGTTATTCAGTTTTCATTTTGAAGATTAGATGGTAGTATGAGTTAGTTAAATCAGGTGATATCCTCCTTTAGAAGTTGATAGCCTATATATGTCATCCTTTGTGGAGGCAATTTAAATAAAATTTAAAACATTTATTCCTGGCTGGGTATGGTGGCTCACTCCTGTAATCCCAGCACTTTGAGAGGCTGAGGCGGGTGGATCACCTGAGGTCAGGAGTTTGAGACCAGCCTGGCCAACATGGTGAAACCCCGTCTTTACTAAAAATACAAAAATTAGCCAAGCATGGTGGCACGTGCCTGTAATCCCAGCTGCTTGGGACACTGAGGCAGGAGAATTGCTTGAACCTGGGGGGCAGAGGTTGCAATGATTGCACCACTGCACTCCAGCCTGGGCGATAGAGTGAGACTCCATCTCAGAAAACGAACAAACAATGTATTCCTTTTAGTATTTTTACATTGTATCAAACTATGGAAGTCCTCTAATTGAGATTAATAAGAAAAAGACAATCTGAATTATAATTTTAAACATTTAACAAGCATGTAGTAAAATAATGATGAAGATAAATAGCATTAGTACAGCAATTAATATTTGTAGCATGCTGACAGTGCTCTGTGTGCGTTTCATATATTAAATTACTCTAATCATCCCAAATCCTGTAAGTTGGGTATCAATTCAAGTGTTCCTATTGGGTAGGAATATACAGTTCTTTTAGGAAATGTAGTATGGTTCTGTGTCTCAAACAGGACACTTACACAGTTGGCCAACATCATCACCTTCTCCATTCTCTGAGATGTTTAGTCTTACTGAGCACTAAATATGGGTCATCAATAGTCCAGACTACCTTGAGCAAACAATAGTCCAGACTACCTTGAGCAAACAGAGCATATACTCATACAGTGTATAAAGAGCACCAAGCATACAGATTTCATGTCTTTCTCATAGTTACTCTTGTAACATGAGCTAAAGATCAGACCTCTATGTCACCTTTGTAACTGATTTCTAGATTTTTTTTTTTTTTTGAGATGGGGTCTTGCCCTGTCACCCAGGCTGGAGTGTAGTGGCGTGATCATGCCTCATTGGAGCCTTCAACTCATGAGCTCAAACAATCCTCCTACCTCAGCTTCCTGAGTAGTTGGGACCACAGGTGTGTGCCACCACACCCAGCTCATTTTTGTATTCTTTGTAGAGATGCAGTCTCACCCTGTTGCCCACGCTGGCCTGGAACTCCTGAGCTCAAAAGATCCCTCCGCCTTGACCTTCCAAAGTGCTGGGATTACAAGCATGAACCACTGCACCCGGCCTAGATTTTTAAATGTGCTTTCCAGTATACACTGAAACTAGAAGTCGACTAAAGAATTACCAAGAGAATTCTATAAAATAGAGATTGAAATGGGGCTCGATGTGGGATGGGTTGGTGATATTGCAGGGAGAAGTAATCTGAGTAAAGGAGGAAAAGAACTGATTTGGGAAAACGATAGTTTTAGTAGTGAGTTTGAGTATGAATTAAGTTGAGATTGAATTTGAATTAAGTTGAGGTTGAATATGAATTAAGTTGAGGTTGAGTTTGAGGTATGAATTAAGATGTGAAATTGATCATTGGAAATGTTAGATTGAGAAAAGTCACAGCTGGATTAATAGCTTCAGAAGTGTGTTTGCAGACAGTTGCAACTAAAGTAATAAGAATAGATGGCCTTGGCCGGGCGCGGTGGCTCACGCCTGTAATCCCAGTACTTTGGGAGGCTGAGGCGAGCAAATCACGAGGTCAGGAGTTCAAGACCAGCCTGGCCCACATGGTGAAACCCCGTCTTTATTAAAAATACAAAAATTAGCTGTGCACAGTGGTGCACGCCTGTAATCCCAGCTACTCGGGAGGCTGAGACAGGAGAATCGCTTGAACCTGGGAGGTGGAGGTTGCAGTGAGCTGAGATCAGTGTGACTGCACTCCAGCCCGGTGACAGAGTGAGACTCTGTGTAAAAAAATAAAATAAATAAAATAATGGCCGTAAGCAAGTAAAGAAGGATGGCCAGCTCTTATTGGGAATGCCTAAATCTAAGGCTTGATCAGAAGTAATGAAACCGTTGGGGCCCTACATTGCTATGACATCCAAAGGGCCATGAATATCAGGAAGAAAGATAATTAACAGGGTCTAATGTTACAGAGAGGTTGAGAGCAAGGAGATTTGATTAAAAGGGTCTTTAGAGCTGATGTCAGGTGTATGATGCCTTTAAGAGCAGTTTTTATAGTGCAGGGGGTGGTCAAAAGAGAAAATAGGTGCTTTCTGAGGTGACGGAGCCTTGAGACTAGCTTATAGTAGTAACTGGGTTATGTCGTGACTTTTATTCTGTGCACCACCCTGTAACATGTACATTTTTATTCCTATTTTCGTAGCATGCTCTAAAGAATGGTGACATTTGTGAAACTTCGGGTAAACCAAAAACCACACCTAAAAGAAAACCTGCTAAGAAGAATAAAAGCCAAAAGAAGAATACTGCAGCTTCCTTACAACAGGTTATTTTAAAATGTTGAGATTTAACTTCAAAGGATGTCTCATTAGTCCTTATTTAATAGTGTAAAATGTCTTTAACTTAAGTGATTAGTACAGTGTTTCTATTGACATATACTTATACAACTTCAAAAACAACTATTAAATTTTCTGTTATTTAGGAACATGCATATTAGTCATGAAAGTATAAAGAATTAGATGGGAATGATAAATGCTAAAATCAGGACATGTGTTCCATTTGTGAATGGAAGGCAGGGAGAAGGTGCCGTTTGGAAGGAGTACCCAAGAGCCGTAAGCTGAATTGGCAGTGTTTTACATCTTAAGCTGAGAGATAGATTTTTTTTTCCCCTTTTTCTTTAAAAACTCTAAAACTGTTAATTCCAAGGAACCCAGAAGTCTAGGTAGATTATTTCTGCTAGTTAAAAGCAGTAGTCCTGAAAGCTGAATATTTTGGTGTCTTTTGAGCCAACTTTAGTTTCATCATTACCAAGGGGGAAGAGAGCTAACAGTTGATGAGCACTTGCTCTAGGCCAGTCCAGAGTGCTGGGCACCATACGCATTTTATCTCCCTCCCGCTATTCACAACAAATATGGGAGGTAGTTTATATTATAGCCATCTAATAAGATGGGGAAACTAAGACTCAAAGAGATTCAGAAACTTGTCCATGATTATAAATGTAAGAGAGTTGGAATTCAGATTTATGTATTTAGACCCCAAGCCTTTCTCATTACATCATTTTGCCTTCCAAATCTCTACCCTCTATCCTTCACCTCCCCACTGATCAAAACGAGATGATAGTTTGCCCTCTTCAAAAGAAATGTGTGCATGTATATATCTTTGATTTCTTTTGTAGTGGAAAGTTGGGGACAAATGTTCTGCCATTTGGTCAGAAGACGGTTGCATTTACCCAGCTACCATTGCTTCAATTGATTTTAAGAGAGAAACCTGTGTTGTGGTTTACACTGGATATGGAAATAGAGAGGAGCAAAATCTGTCCGATCTACTTTCCCCAATCTGTGAAGTAGCTAATAATATAGAACAAAATGCTCAAGAGGTAAGGATACAAAAAAAAAAAAATTCAATTTCTGGAAGCAGAGACTAGATGAGAAACTGTTAAACAGTATACACAGTTGTCAGTTTGATCCACCGAGGCATTAATTTTTTCTTAATCACACCCTTATAACAAAAACCTGCATATTTTTTCTTTTTAAAGAATGAAAATGAAAGCCAAGTTTCAACAGATGAAAGTGAGAACTCCAGGTCTCCTGGAAATAAATCAGATAACATCAAGCCCAAATCTGCTCCATGGAACTCTTTTCTCCCTCCACCACCCCCCATGCCAGGGCCAAGACTGGGACCAGGAAAGGTAAACCTTCTATGAAAGTTTTCCAGAAAATAGTTAATGTCGGGACATTTAACCTCTCTGTTAACTAATTTGTAGCTCTCCCATGAAACTTTTGTAGCTTAAATACACAAGAATTTTTTGAAAAGGAAATAAGATAATGATGCAAAATAGTTAATTTTTTAAAAAAATGTTAGACACTGCAGTGGATGCAACAAAATACTTTATATGAAAGATTTATCCAGTTAACTTTTGTGGAGTATTAGGTATTAGACTAATAATTAGCACACTTACTTAAGTTAGAAAGTATAATAATGCGCCGGACGCGGTAGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCAAGGTGGGCGGATCACAAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCATCTCTACTGAAAATACAAAAAAATTTGCCGGGCGTGATGGCGGGCACCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGGATGGTGTGAACCCCGGAGGCAGAGCTTGCAGTGAGTCAAGATCGTGCCACTGCACTCCAACCTGGGCGACAGAATGAGACTCCATCTCAAACAAAAAAACAAAACAAAACAAAAAAAAGTGTAATAATAATTTATCATTAGCTGGATGATATGCTGTTGTTTCCCATGTCACCTGTATAAGATATGTAAAATAAGAACACATTATTTACATCTAATATAGATAAAATCCTGAGGCGCTCTCAGATTGTTTTGTAGAGTTCAAATGTAAATATTGTTTTCATTTATGGTCCTTTTGGTTATAAGTAACAGAAATCAACTCTAAAAAGATTTTTATTATAGGTTAGATTATGTCATGGAACCTTAAGGCTTGTCCCTTTCTAGTTCTTTTGTGTAAAGCGGTGATTTCTTCCATGGAGGGAATGGTATTTAGGCAATTTTTTTTTTTTTTCGAGATGGAGTCTTGCTCTGTCGCTCAGGCTGGAGTGCAGTGGCACCATTTCAGCTCACTGCAACTTCCACCTCCTGGGTTCAAGTGATTCTCCTGCTTCAGCCTCCCAAGTAGCTGAGATTACAGGCACCCGCCACCACACCCGGCTTATTTTGTATTTTTAGTAGAGATGGGGTTTCACCATGTTGGCCAGGCTGGTCTTGAACTCCTGACCTCAAGTGATCTCCCCACCTTGGCCTTCCAAAGTGCTAGGATTACAGGCGCCTAGCCTAGGCAGTCATTTTCAAAAAACAAGCATGACTCACCAAAAGTTTTAAGATTTTCTGTGATAATGTTCTTATTGAGGCTTACATTATATTACAGTTTCTTGAATCTAAAATGATGTACCCTCTTAGGATATATACATCATGCTTCATTGGTCTCAGGGGGCTGATTTTTATAAGGAGAGATTTGCTAGTTTTCACAATATGTCCTCTAAGTTGGCATGTATAGCTAAACAGGCTTTCATAAAAATATACAATTTAGTTAATGAAATTTGGGATATAGTCTTTTATGATTGAAATAATTTTGCTAAATAGACTGTCTCTGATTTATTAGGTAATCACCACTCTTATTTTGTTTTACTTCCTTAATGTCTACATAGAAAGGAAATGAGAAAAATCCAGAGGTTGTCATTTGACTTATGAGTCTGTTTGACTTCAGGATTTGGTACATGAAATTTCACTTAATCTTTTTGATATGTATAAAACAAATATTCTGGGTAATTATTTTTATCCTTTTGGTTTTGAGTCCTTTTTATTCCTATCATATTGAAATTGGTAAGTTAATTTTCCTTTGAAATATTCCTTATAGCCAGGTCTAAAATTCAATGGCCCACCACCGCCACCGCCACCACCACCACCCCACTTACTATCATGCTGGCTGCCTCCATTTCCTTCTGGACCACCAGTAAGTAAAAAAGAGTATAGGTTAGATTTTGCTTTCACATACAATTTGATAATTAGCAGAATAGAGGATTGTAAAATGTCATTGTAGAACATCCCTTGGGCCAGATTCTAATGGGTAGAAATTTGAACTAAACCTCTGGGTTTTGTTTGTTTTTAATGCCTTTCTGTTACCCAGATGCAGTGCTCTTGTAGTCCCAAGTCTAAGCTCTAGGTTGCCTTCTTTCCTGGCAGAAGTTGGTGTCTATGCCATAAGGAGGTAGTTCCTGTTAGAAGGGATTTAATTATACCTTATATAAGGAATTAGTGTTTGCCCTTCTAGGTATAGTTGGATGTTAGCTTCTGATGTAAACTGGATTTCTTTTTCTTTCTCTCTCTTTTTTTTTTTTTGTTTTGGAGGCAGAGTTTTGCCCTTGTACCCCAGGCTGGAGTGCAGTGGTGTGATCTCAGCTCACAGCAACCTCCGCCTCCTGGGTTCAAGCAATTCTGCCTCGGCCTCCCA-G Werdnig-Hoffmann disease Pathogenic (Sep 04, 2019)692109
5-70938841-C-T Benign (Jul 28, 2017)448432
5-70938845-G-A Spinal muscular atrophy, type II Pathogenic (Jan 01, 2005)9175
5-70938848-T-TCTGA Pathogenic/Likely pathogenic (Jun 23, 2017)448433
5-70938865-T-TA Likely pathogenic (Aug 29, 2017)586624
5-70938888-A-T Kugelberg-Welander disease Pathogenic (Jan 01, 2005)9172
5-70938889-T-TA Likely pathogenic (May 02, 2017)448427
5-70941458-G-A Uncertain significance (Sep 07, 2022)1807337
5-70941477-A-T Uncertain significance (Nov 21, 2018)805484
5-70941503-C-T Werdnig-Hoffmann disease Likely pathogenic (Dec 06, 2023)2664372
5-70942356-AGTGGAAAGTTG-A Pathogenic (Mar 18, 2016)634945
5-70942362-A-C Kugelberg-Welander disease Uncertain significance (Apr 03, 2019)638580
5-70942364-G-T Werdnig-Hoffmann disease Likely pathogenic (-)929467
5-70942367-G-C Kugelberg-Welander disease Pathogenic (Mar 18, 2016)9176
5-70942372-CA-C Spinal muscular atrophy Pathogenic (Feb 02, 2022)1699436
5-70942389-G-A Spinal muscular atrophy, type II • Kugelberg-Welander disease Pathogenic (Mar 15, 2016)9173

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
SMN1protein_codingprotein_codingENST00000380707 829002
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.01580.480124181051241860.0000201
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.058477.450.9403.11e-71916
Missense in Polyphen32.39971.2501802
Synonymous-0.86142.331.729.98e-8569
Loss of Function-0.62721.251.615.19e-8207

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.00006200.0000618
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.00004620.0000462
European (Non-Finnish)0.00002710.0000271
Middle Eastern0.000.00
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: The SMN complex plays a catalyst role in the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome. Thereby, plays an important role in the splicing of cellular pre-mRNAs. Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP. In the cytosol, the Sm proteins SNRPD1, SNRPD2, SNRPE, SNRPF and SNRPG are trapped in an inactive 6S pICln-Sm complex by the chaperone CLNS1A that controls the assembly of the core snRNP. Dissociation by the SMN complex of CLNS1A from the trapped Sm proteins and their transfer to an SMN-Sm complex triggers the assembly of core snRNPs and their transport to the nucleus. Ensures the correct splicing of U12 intron-containing genes that may be important for normal motor and proprioceptive neurons development. Also required for resolving RNA-DNA hybrids created by RNA polymerase II, that form R-loop in transcription terminal regions, an important step in proper transcription termination. May also play a role in the metabolism of small nucleolar ribonucleoprotein (snoRNPs). {ECO:0000269|PubMed:18984161, ECO:0000269|PubMed:23063131, ECO:0000269|PubMed:26700805, ECO:0000269|PubMed:9845364}.;
Disease
DISEASE: Spinal muscular atrophy 1 (SMA1) [MIM:253300]: A form of spinal muscular atrophy, a group of neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. Autosomal recessive forms are classified according to the age of onset, the maximum muscular activity achieved, and survivorship. The severity of the disease is mainly determined by the copy number of SMN2, a copy gene which predominantly produces exon 7- skipped transcripts and only low amount of full-length transcripts that encode for a protein identical to SMN1. Only about 4% of SMA patients bear one SMN1 copy with an intragenic mutation. SMA1 is a severe form, with onset before 6 months of age. SMA1 patients never achieve the ability to sit. {ECO:0000269|PubMed:10732817, ECO:0000269|PubMed:14715275, ECO:0000269|PubMed:15249625, ECO:0000269|PubMed:15580564, ECO:0000269|PubMed:7813012, ECO:0000269|PubMed:9147655}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Spinal muscular atrophy 2 (SMA2) [MIM:253550]: An autosomal recessive form of spinal muscular atrophy, a neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. It has intermediate severity, with onset between 6 and 18 months. Patients do not reach the motor milestone of standing, and survive into adulthood. {ECO:0000269|PubMed:10732802, ECO:0000269|PubMed:14715275, ECO:0000269|PubMed:9158159, ECO:0000269|PubMed:9837824}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Spinal muscular atrophy 3 (SMA3) [MIM:253400]: An autosomal recessive form of spinal muscular atrophy, a neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. Onset is after 18 months. Patients develop ability to stand and walk and survive into adulthood. {ECO:0000269|PubMed:10732817, ECO:0000269|PubMed:14715275, ECO:0000269|PubMed:9158159, ECO:0000269|PubMed:9837824}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Spinal muscular atrophy 4 (SMA4) [MIM:271150]: An autosomal recessive form of spinal muscular atrophy, a neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. Onset is in adulthood, disease progression is slow, and patients can stand and walk. {ECO:0000269|PubMed:7658877, ECO:0000269|PubMed:8551862}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
RNA transport - Homo sapiens (human);snRNP Assembly;Metabolism of RNA;Metabolism of non-coding RNA (Consensus)

Recessive Scores

pRec
0.230

Haploinsufficiency Scores

pHI
0.0969
hipred
N
hipred_score
0.390
ghis
0.621

Essentials

essential_gene_CRISPR
E
essential_gene_CRISPR2
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.801

Gene Damage Prediction

AllRecessiveDominant
MendelianLowLowLow
Primary ImmunodeficiencyLowLowLow
CancerLowLowLow

Mouse Genome Informatics

Gene name
Smn1
Phenotype
growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); muscle phenotype; craniofacial phenotype; homeostasis/metabolism phenotype; cellular phenotype; skeleton phenotype; embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; digestive/alimentary phenotype; limbs/digits/tail phenotype; hearing/vestibular/ear phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan);

Zebrafish Information Network

Gene name
smn1
Affected structure
primary motor neuron
Phenotype tag
abnormal
Phenotype quality
swollen

Gene ontology

Biological process
spliceosomal complex assembly;spliceosomal snRNP assembly;DNA-templated transcription, termination;nervous system development;import into nucleus
Cellular component
nucleus;nucleoplasm;cytoplasm;cytosol;Cajal body;Z disc;SMN complex;SMN-Sm protein complex;cytoplasmic ribonucleoprotein granule;neuron projection;perikaryon;Gemini of coiled bodies
Molecular function
RNA binding;protein binding;identical protein binding